What's in Université de Montréal's pipeline?

Université de Montréal has 2 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Université de Montréal's portfolio?

Top competitors by shared drug class: Eli Lilly and Company, Tarsa Therapeutics, Inc., University of Missouri-Columbia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universit-de-montr-al.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Université de Montréal — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Université de Montréal pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Intranasal calcitonin	Intranasal calcitonin	marketed	Calcitonin receptor agonist	Calcitonin receptor	Endocrinology / Bone metabolism

Therapeutic area mix

Endocrinology / Bone metabolism · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Eli Lilly and Company · 1 shared drug class
Tarsa Therapeutics, Inc. · 1 shared drug class
University of Missouri-Columbia · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Université de Montréal:

Cite this brief

Drug Landscape (2026). Université de Montréal — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universit-de-montr-al. Accessed 2026-05-17.